Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical ...

Chimeric antigen receptor (CAR) T-cell immunotherapy was reported by ASCO in 2018 as the advance of the year. This innovative cancer treatment originated from intensive experimental work in academic ...

Prof. LIANG Xingjie's team from the National Center for Nanoscience and Technology, along with Prof. GONG Ningqiang from the University of Science and Technology of China, has developed a biomimetic ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.